Stomach paralysis, medically called gastroparesis, is a condition where the stomach loses its ability to move food into the small intestine at a normal pace. Ozempic (semaglutide) has been linked to a roughly 3.7 times higher risk of developing this condition compared to people using other weight-loss medications. While some degree of slowed digestion is actually how the drug works, a small number of users develop a more severe and persistent form that goes beyond typical side effects.
How Ozempic Slows Your Stomach
Ozempic mimics a natural hormone called GLP-1 that your gut releases after eating. This hormone acts on three key targets: the pancreas, where it triggers insulin release; the brain’s hunger centers, where it creates a feeling of fullness; and nerve cells in the stomach wall, where it slows the muscle contractions that push food forward. That deliberate slowing is a core part of how the drug controls blood sugar and reduces appetite. You feel full longer because food literally sits in your stomach longer.
For most people, this effect is mild and manageable. But in some cases, the stomach slows down so much that it essentially stalls. Food sits for hours longer than it should, fermenting and stretching the stomach, which triggers a cascade of symptoms that can become debilitating.
How Common Is It?
A large retrospective study of over 55,000 people found that gastroparesis occurred at a rate of 6.5 per 1,000 person-years among semaglutide users, compared to 2.1 per 1,000 person-years for people taking a different weight-loss drug (bupropion-naltrexone). Among the different semaglutide products, Ozempic had the highest rate at 7.2 per 1,000 person-years, while the oral tablet form (Rybelsus) had the lowest at 3.7 per 1,000 person-years.
To put that in practical terms: the vast majority of Ozempic users will not develop gastroparesis. But the risk is real enough that the FDA updated the Ozempic label in October 2025 to include a specific warning. The label now states that Ozempic “is not recommended in patients with severe gastroparesis” and notes that severe gastrointestinal reactions were reported more frequently with Ozempic than with placebo in clinical trials.
Normal Side Effects vs. Gastroparesis
This is the distinction that matters most. Nausea, mild bloating, and occasional queasiness are extremely common when starting Ozempic or increasing the dose. These effects typically ease after about 20 weeks of use as the body adjusts. They’re unpleasant but expected.
Gastroparesis is different. The hallmark symptoms include:
- Persistent vomiting, sometimes of food eaten many hours earlier
- Severe nausea that doesn’t fade with time or dose adjustment
- Abdominal pain and bloating that worsens after meals
- Feeling full after just a few bites
- Unintended weight loss from inability to keep food down
The key difference is severity and persistence. If you’re still vomiting regularly after several months on a stable dose, or if you’re throwing up food you ate six or eight hours ago, that pattern points toward gastroparesis rather than ordinary adjustment side effects.
What Happens Inside a Paralyzed Stomach
When the stomach can’t empty properly, food accumulates and can form hardened masses called bezoars. These are clumps of undigested material, often fiber-heavy foods, that compact together over time. Bezoars can press against the stomach lining and cause ulcers or bleeding. In more serious cases, they can block the stomach’s exit entirely or cause obstruction further down in the intestines.
Even without bezoar formation, prolonged gastroparesis creates problems. Repeated vomiting can lead to dehydration and electrolyte imbalances. Reduced food intake causes nutritional deficiencies. The condition can also interfere with how other medications are absorbed, since pills may sit in the stomach far longer than expected before reaching the bloodstream.
Other Serious Digestive Risks
Gastroparesis is not the only gastrointestinal concern linked to GLP-1 drugs like Ozempic. Research from the University of British Columbia found that users also faced a 4.2 times higher risk of bowel obstruction, where food gets blocked in the small or large intestine, causing cramping, bloating, and vomiting. The same study found a 9 times higher risk of pancreatitis, an inflammation of the pancreas that can cause severe abdominal pain and sometimes requires hospitalization or surgery.
Does It Reverse After Stopping?
For many people, stopping the medication allows normal stomach motility to return. One therapeutic approach is to discontinue Ozempic and monitor whether symptoms resolve. Because semaglutide stays active in the body for weeks after the last injection, improvement may not be immediate. Doctors sometimes recommend waiting up to four weeks off the medication before re-testing gastric emptying to get an accurate picture.
There’s a complication, though. Some patients continue to experience symptoms even after the drug has cleared their system and even when a follow-up gastric emptying test comes back normal. This may happen because GLP-1 drugs affect the vagus nerve, which controls stomach contractions, and those effects can linger independently of whether the stomach is technically emptying at a normal speed. In other words, the nerves may remain sensitized even after the direct drug effect has worn off.
A smaller number of patients appear to develop true, lasting gastroparesis that persists long after stopping the medication. Whether the drug caused new nerve damage or unmasked a pre-existing vulnerability that hadn’t yet produced symptoms remains an open question. People with diabetes are already at elevated risk for gastroparesis because high blood sugar can damage stomach nerves over time, which makes it harder to untangle what the drug caused versus what was already developing.
Who Faces Higher Risk
The clearest risk factor is having pre-existing gastroparesis or significant digestive motility problems before starting the drug. The FDA label explicitly warns against using Ozempic in people with severe gastroparesis. Beyond that, people with long-standing diabetes are at higher baseline risk because the disease itself damages the nerves that control stomach movement.
Dose also appears to matter. In clinical trials, severe gastrointestinal reactions occurred at roughly twice the rate with the 1 mg dose (0.8%) compared to the 0.5 mg dose (0.4%). The injectable forms of semaglutide (Ozempic and Wegovy) showed higher gastroparesis rates than the oral tablet, likely because of differences in how the drug is absorbed and how much reaches the stomach’s nerve cells.
If you’re experiencing symptoms that go beyond the typical early-phase nausea, particularly vomiting undigested food hours after eating or worsening abdominal pain that doesn’t improve as your body adjusts, those are signs worth raising with your prescriber sooner rather than later. Gastroparesis is diagnosable with a gastric emptying study, a straightforward imaging test that tracks how quickly a standard meal moves through your stomach.